Nanoparticle-based delivery systems as emerging therapy in retinoblastoma : recent advances, challenges and prospects
This journal is © The Royal Society of Chemistry..
Retinoblastoma is the most common intraocular malignancy in children. The treatment of this rare disease is still challenging in developing countries due to delayed diagnosis. The current therapies comprise mainly surgery, radiotherapy and chemotherapy. The adverse effects of radiation and chemotherapeutic drugs have been reported to contribute to the high mortality rate and affect patients' quality of life. The systemic side effects resulting from the distribution of chemotherapeutic drugs to non-cancerous cells are enormous and have been recognized as one of the reasons why most potent anticancer compounds fail in clinical trials. Nanoparticulate delivery systems have the potential to revolutionize cancer treatment by offering targeted delivery, enhanced penetration and retention effects, increased bioavailability, and an improved toxicity profile. Notwithstanding the plethora of evidence on the beneficial effects of nanoparticles in retinoblastoma, the clinical translation of this carrier is yet to be given the needed attention. This paper reviews the current and emerging treatment options for retinoblastoma, with emphasis on recent investigations on the use of various classes of nanoparticles in diagnosing and treating retinoblastoma. It also presents the use of ligand-conjugated and smart nanoparticles in the active targeting of anticancer and imaging agents to the tumour cells. In addition, this review discusses the prospects and challenges in translating this nanocarrier into clinical use for retinoblastoma therapy. This review may provide new insight for formulation scientists to explore in order to facilitate the development of more effective and safer medicines for children suffering from retinoblastoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Nanoscale advances - 5(2023), 18 vom: 12. Sept., Seite 4628-4648 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Onugwu, Adaeze Linda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1039/d3na00462g |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362030413 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362030413 | ||
| 003 | DE-627 | ||
| 005 | 20240308232041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1039/d3na00462g |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM362030413 | ||
| 035 | |a (NLM)37705787 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Onugwu, Adaeze Linda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanoparticle-based delivery systems as emerging therapy in retinoblastoma |b recent advances, challenges and prospects |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a This journal is © The Royal Society of Chemistry. | ||
| 520 | |a Retinoblastoma is the most common intraocular malignancy in children. The treatment of this rare disease is still challenging in developing countries due to delayed diagnosis. The current therapies comprise mainly surgery, radiotherapy and chemotherapy. The adverse effects of radiation and chemotherapeutic drugs have been reported to contribute to the high mortality rate and affect patients' quality of life. The systemic side effects resulting from the distribution of chemotherapeutic drugs to non-cancerous cells are enormous and have been recognized as one of the reasons why most potent anticancer compounds fail in clinical trials. Nanoparticulate delivery systems have the potential to revolutionize cancer treatment by offering targeted delivery, enhanced penetration and retention effects, increased bioavailability, and an improved toxicity profile. Notwithstanding the plethora of evidence on the beneficial effects of nanoparticles in retinoblastoma, the clinical translation of this carrier is yet to be given the needed attention. This paper reviews the current and emerging treatment options for retinoblastoma, with emphasis on recent investigations on the use of various classes of nanoparticles in diagnosing and treating retinoblastoma. It also presents the use of ligand-conjugated and smart nanoparticles in the active targeting of anticancer and imaging agents to the tumour cells. In addition, this review discusses the prospects and challenges in translating this nanocarrier into clinical use for retinoblastoma therapy. This review may provide new insight for formulation scientists to explore in order to facilitate the development of more effective and safer medicines for children suffering from retinoblastoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Ugorji, Onyinyechi Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Ufondu, Chinasa A |e verfasserin |4 aut | |
| 700 | 1 | |a Ihim, Stella Amarachi |e verfasserin |4 aut | |
| 700 | 1 | |a Echezona, Adaeze Chidiebere |e verfasserin |4 aut | |
| 700 | 1 | |a Nwagwu, Chinekwu Sherridan |e verfasserin |4 aut | |
| 700 | 1 | |a Onugwu, Sabastine Obinna |e verfasserin |4 aut | |
| 700 | 1 | |a Uzondu, Samuel WisdomofGod |e verfasserin |4 aut | |
| 700 | 1 | |a Agbo, Chinazom Precious |e verfasserin |4 aut | |
| 700 | 1 | |a Ogbonna, John Dike |e verfasserin |4 aut | |
| 700 | 1 | |a Attama, Anthony Amaechi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanoscale advances |d 2019 |g 5(2023), 18 vom: 12. Sept., Seite 4628-4648 |w (DE-627)NLM295535059 |x 2516-0230 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2023 |g number:18 |g day:12 |g month:09 |g pages:4628-4648 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1039/d3na00462g |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2023 |e 18 |b 12 |c 09 |h 4628-4648 | ||